Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Cerevance
1 Marina Park Dr
Boston, MA 02210
Phone: (408) 220-5722
https://cerevance.com/

Cerevance is a private pharmaceutical company with a focus on CNS disorders. CVN424, Cerevance lead therapeutic, is a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6), that demonstrated significant and clinically meaningful efficacy in a 135-patient Phase 2 study in patients with Parkinson's disease. The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify highly selectively expressed, novel target proteins that are either specific to certain brain circuits or are over- or under-expressed in diseased brains. Partnering with over 25 brain banks and evaluating an expanding collection of more than 12,000 human post-mortem brain tissue samples, Cerevance is advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson's disease, Amyotrophic Lateral Sclerosis and Alzheimer's disease.

Key Contact
Name
Craig Thompson
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
02/13/23 $51,000,000 Series B Dementia Discovery Fund
Dolby Family Ventures
Foresite Capital
Gates Frontier
GV
Lightstone Ventures
Takeda Ventures
UPMC Enterprises
undisclosed
04/25/24 $47,000,000 Series B-1 Extension Agent Capital
Bioluminescence Ventures
Double Point Ventures
Gates Frontier
GV
LifeRock Ventures
Lightstone Ventures
MQB Partners
undisclosed